# Function of TCF-1 in antagonizing malignancy

> **NIH NIH R21** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2021 · $220,000

## Abstract

The human immune system is naturally capable of killing cancer cells. But mutations and other
abnormalities handicap or neutralize it, making the immune system insufficient and ineffective.
Currently there is a lot of investment being made to study how to stimulate the immune system to
kill cancer cells. However, there is evidence that in certain circumstances boosting the immune
system actually encourages cancer cell growth. We’re trying to understand how this phenomenon
works. Particularly, under the circumstances when a TCF-1 gene mutation is involved — the
immune system, when stimulated, actually promotes the growth of lymphoma. We expect to learn
how TCF-1 gene regulates the immune responses to affect the lymphoma development.

## Key facts

- **NIH application ID:** 10281056
- **Project number:** 1R21AI163256-01
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** Zuoming Sun
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $220,000
- **Award type:** 1
- **Project period:** 2021-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10281056

## Citation

> US National Institutes of Health, RePORTER application 10281056, Function of TCF-1 in antagonizing malignancy (1R21AI163256-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10281056. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*